Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial

(2014) Joel L. Johnson et al.   PLoS One

Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study

(2013) Harvey D. White et al.   Journal of the American Heart Association

Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial

(2012) P. M. Ridker et al.   CLINICAL CHEMISTRY

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

(2012) Ph Gabriel Steg et al.   EUROPEAN HEART JOURNAL

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

(2010) Harvey White et al.   AMERICAN HEART JOURNAL

Concept of Vulnerable/Unstable Plaque

(2010) Aloke V. Finn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis

(2010) Deepak L. Bhatt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality

(2010)   JOURNAL OF INTERNAL MEDICINE

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE